Business Wire

Jabil Packaging Solutions Signs New Plastics Economy Global Commitment

Share

Jabil Packaging Solutions (JPS), a division of Jabil Inc. (NYSE: JBL), announced today that it is a signatory of the New Plastics Economy Global Commitment, an initiative led by the Ellen MacArthur Foundation in collaboration with the United Nations Environment Programme (UNEP). Uniting businesses, governments and other organizations behind a common vision and targets to address plastic waste and pollution at its source, the Global Commitment brings Jabil Packaging Solutions together with more than 400 signatories, including nearly 200 businesses representing over 20 percent of the global plastic packaging market.

As a signatory of the Ellen MacArthur Foundation Global Commitment, Jabil Packaging Solutions is committed to changing how we produce, use and reuse plastic by eliminating the material we don’t need; innovating so the plastic we do need is designed to be safely reused, recycled or composted; and circulating plastic we use to keep it in the economy and out of the environment.

Commenting on Jabil Packaging Solutions’ commitment, JPS CEO Brenda Chamulak said, “We are incredibly energized about working with the Ellen MacArthur Foundation on the New Plastics Economy Global Commitment. As a custom packaging solution provider, we are in a unique position to help the world’s biggest brands reimagine and rejuvenate their packaging portfolios with the ultimate goal of diverting them from the waste stream.”

Launched in October 2018 and signed by major brands, including Nestlé, PepsiCo and Target Corporation, the New Plastics Economy Global Commitment has quickly become one of the preeminent agreements to transform the plastic packaging sector.

By 2025, Jabil Packaging Solutions has pledged to eliminate problematic or unnecessary plastic packaging in customers’ packaging; move from single-use toward reuse models; increase use of post-consumer recycled content in customer packaging; and make 100 percent of customers’ plastic packaging reusable, recyclable or compostable. Progress toward these goals will be measured and reported on annually through the New Plastics Economy Global Commitment Report.

According to Jabil’s Sustainable Packaging Trends survey, over half (53%) of the companies surveyed have clearly defined goals with measurable targets, but only 36% of them are certain they can meet their goals. To help its customers meet their sustainability goals, JPS recently launched a services engagement framework that enables packaged goods brands to rapidly design and deliver innovative, sustainable packaging formats into the marketplace. This new solution from JPS comprises three services that accelerate the new product development process while dramatically reducing the risk associated with developing sustainable packaging formats, including:

  • Design for Sustainability: Drive faster time-to-market and eco-friendly validation with a proven design innovation process.
  • Sustainable Packaging Assessment: Iteratively assess key sustainability factors, such as carbon footprint and recyclability, in parallel with critical new product introduction requirements.
  • Materials Sourcing and Development: Introduce holistic procurement strategies that account for price, supply chain optimization and performance

JPS is also experiencing commercial traction around the concept of combining reusable inserts with durable sensing and dispensing devices that can enable less waste and smarter consumption. “By removing romance packaging from the equation, our device and digital solutions can make a big impact on reduce and reuse,” said Jason Paladino, vice president of technology at JPS. “New technologies and packaging ecosystems are not only going to help us eliminate a lot of unnecessary plastic packaging, they are also going to reduce the amount of product we waste through spoilage and overconsumption.”

JPS recently held a webinar on key sustainability challenges and solutions for packaged goods companies. This interactive discussion featured information from a survey of more than 200 packaging decision-makers as well as an overview of the real packaging solutions that are driving change. Visit jabil.com to sign up and watch the on-demand version.

About Jabil

Jabil (NYSE: JBL) is a manufacturing solutions provider that delivers comprehensive design, manufacturing, supply chain and product management services. Leveraging the power of over 200,000 people across 100 sites strategically located around the world, Jabil simplifies complexity and delivers value in a broad range of industries, enabling innovation, growth and customer success. For more information, visit jabil.com.

Contact information

Erin Vadala/Warner Communications
erin@warnerpr.com
978.468.3076

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed13.12.2019 21:55:00 EETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication. This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who: Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or Are homozygous for the F508del mutation or Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1

CreditLens™ Solution Receives SOC 2 Attestation Report13.12.2019 18:17:00 EETPress release

Moody’s Analytics announced today that the CreditLens software-as-a-service (SaaS) solution has received an attestation report from the American Institute of Certified Public Accountants (AICPA) System and Organization Controls (SOC 2). The SOC 2 report details the security and availability of customer data in the CreditLens SaaS solution, and denotes its adherence to the AICPA’s security and availability controls standards. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It facilitates process automation and helps clients improve their efficiency, reduce errors, and streamline workflows. A SOC 2 report ensures that a company’s information security measures are in line with the unique parameters of today’s cloud requirements. The report addresses a service organization's controls that relate to operations and compliance, as outlined by the AICPA's Tru

CHMP Grants Positive Opinion for Expanded Use of Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible13.12.2019 14:47:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex®▼ (daratumumab) to include the use of daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of adult patients with newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The Positive Opinion is supported by data from Part 1 of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet 3 in June 2019, and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. Additional information about this study can be found at www.ClinicalTrials.gov (NCT02541383). “Today’s Opinion takes us a step closer to offering the first daratumumab combination regimen to transplant eligible patients, redefining treatment for those people newl

Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer13.12.2019 14:40:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending approval for expanding the use of Erleada® (apalutamide) to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).2 The CHMP’s Positive Opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the new use of apalutamide. The Positive Opinion is based on data from the Phase 3 TITAN study, which assessed the addition of apalutamide to ADT – the current standard of care in mHSPC – in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis. The dual primary endpoints of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Ap

German Player Karl Rupprec Wins 2019 Boyaa Poker Tournament Europe13.12.2019 12:24:00 EETPress release

On December 8, the sixth edition of the BPT (Boyaa Poker Tournament) came to an end. King's Resort in the Czech Republic celebrated this BPT Europe that enjoyed 600 cumulative participants from 20 countries. In the end, Karl Rupprec, from Germany, won the Main Event Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005109/en/ (Photo: Business Wire) Highlights of the BPT Europe 2019 final The BPT Europe 2019 Main Event began on December 8 at 2:00 p.m., Czech Republic time. After 9 hours of Texas Poker, players Ondrej Drozd from the Czech Republic and Karl Rupprec from Germany reached the last heads-up. In the end, Karl Rupprec, who started with half of his opponent's chips, reversed the situation with his two nines, winning the championship. Heads-up Highlights: Karl Rupprec pair 9 and Ondrej Drozd 2, 5. The flop was 2, Q, 9, so Karl Rupprec got three of a kind, and Ondrej Drozd got pair 2. Rupprec pretended

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Italian Designed Architectural Lighting Brand for Motorized Luminaire with Smart Wireless Controls13.12.2019 12:00:00 EETPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that it has achieved smart lighting design with SunLike Series natural spectrum LEDs in cooperation with Casambi Technologies Oy (“Casambi”), a leading developer of wireless lighting control systems based on Bluetooth Low Energy (BLE), and it has been adopted for the Italian designed architectural lighting brand formalighting Ltd. (“formalighting”), a global manufacturer of Italian designed architectural lighting systems and solutions for a new product line which offers motorized luminaire with smart wireless controls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005009/en/ SunLike implemented in motion lamps (Photo: Business Wire) The SunLike COB LED packages have been adopted by formalighting for the new fixtures, Moto-Zero 40 Compasso and Moto-Zero 66 Zoom, in track mounted motorized spotlight range. In this sect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom